Immunotherapy Removes Surgery Need in dMMR Cancers: AACR 2025
Neoadjuvant immunotherapy using PD-1 blockade has demonstrated the potential to eliminate the need for surgery in patients with early-stage mismatch repair-deficient (dMMR) cancers, according to groundbreaking data presented at the AACR Annual Meeting 2025.